EP 4237082 A1 20230906 - VECTORIZED ANTI-CGRP AND ANTI-CGRPR ANTIBODIES AND ADMINISTRATION THEREOF
Title (en)
VECTORIZED ANTI-CGRP AND ANTI-CGRPR ANTIBODIES AND ADMINISTRATION THEREOF
Title (de)
VEKTORISIERTE ANTI-CGRP- UND ANTI-CGPR-ANTIKÖRPER UND VERABREICHUNG DAVON
Title (fr)
ANTICORPS VECTORISÉS ANTI-CGRP ET ANTI-RÉCEPTEUR DE CGRP ET LEUR ADMINISTRATION
Publication
Application
Priority
- US 202063106854 P 20201028
- US 2021057155 W 20211028
Abstract (en)
[origin: US2024124890A1] Compositions and methods are described for the delivery of a fully human post-translationally modified therapeutic monoclonal antibody that binds to CGRP or CGRP receptor to a human subject for the treatment or prevention of migraines and cluster headaches. The antibodies may be delivered by gene therapy vectors, particularly rAAV vectors. Also provided are dual transgene constructs for the delivery of anti-CGRP and anti-CGRP receptor antibodies or antigen binding fragments thereof.
IPC 8 full level
A61P 25/06 (2006.01); A61K 48/00 (2006.01); C07K 16/18 (2006.01); C12N 15/864 (2006.01)
CPC (source: EP US)
A61K 48/0058 (2013.01 - EP US); A61P 25/06 (2018.01 - EP US); C07K 16/18 (2013.01 - EP US); C07K 16/28 (2013.01 - US); C12N 15/86 (2013.01 - EP US); A61K 2039/505 (2013.01 - US); A61K 2039/54 (2013.01 - EP US); C07K 2317/24 (2013.01 - EP); C07K 2317/55 (2013.01 - US); C07K 2317/622 (2013.01 - EP); C07K 2317/76 (2013.01 - EP); C12N 2750/14122 (2013.01 - EP US); C12N 2750/14143 (2013.01 - EP US); C12N 2750/14145 (2013.01 - EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
DOCDB simple family (application)
US 202118034330 A 20211028; EP 21811651 A 20211028